Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Envveno Medical Corp
(NQ:
NVNO
)
5.700
+0.040 (+0.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Envveno Medical Corp
< Previous
1
2
Next >
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
June 25, 2024
Via
ACCESSWIRE
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
June 21, 2024
Via
ACCESSWIRE
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
June 17, 2024
Via
ACCESSWIRE
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024
Via
ACCESSWIRE
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
April 24, 2024
Via
ACCESSWIRE
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
April 09, 2024
Via
ACCESSWIRE
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
March 15, 2024
Via
ACCESSWIRE
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
December 14, 2023
Via
ACCESSWIRE
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
March 06, 2024
Via
ACCESSWIRE
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
February 29, 2024
Via
ACCESSWIRE
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
February 20, 2024
Via
ACCESSWIRE
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
November 16, 2023
Via
ACCESSWIRE
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 26, 2023
Via
ACCESSWIRE
enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference
October 12, 2023
Via
ACCESSWIRE
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial
October 06, 2023
Via
ACCESSWIRE
enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve
October 06, 2023
Via
ACCESSWIRE
enVVeno Medical Announces Private Placement of $28 Million
October 06, 2023
Via
ACCESSWIRE
enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update
July 31, 2023
Via
ACCESSWIRE
enVVeno Medical to Host Virtual KOL Event on July 18, 2023
July 14, 2023
Via
ACCESSWIRE
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events
July 05, 2023
Via
ACCESSWIRE
enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 01, 2023
Via
ACCESSWIRE
enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
March 02, 2023
Via
ACCESSWIRE
enVVeno Medical to Present at Cowen's 43rd Annual Health Care Conference
February 08, 2023
Via
ACCESSWIRE
enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study
November 07, 2022
Via
ACCESSWIRE
enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 27, 2022
Via
ACCESSWIRE
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer
January 18, 2023
Via
ACCESSWIRE
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
January 11, 2023
Via
ACCESSWIRE
Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues
November 17, 2022
Via
ACCESSWIRE
enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference
September 22, 2022
Via
ACCESSWIRE
enVVeno Medical to Host Conference Call and Webcast on September 21, 2022
September 19, 2022
Via
ACCESSWIRE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.